Skip to main content
Online First
Original Research, Pediatric Cancer, Transplant
Letermovir Prophylaxis After Stem Cell Transplant in Pediatric Patients Aged Younger than 12 Years
Teaghan T. Chen, PharmD; Alexandria David, PharmD, BCPPS; Amanda Strommen, PharmD, BCOP; Erin Barthelmess, PharmD, BCOP; Laura McLaughlin, MD
Read More
Online First
Practical Issues in Pharmacy Management, Adverse Events, Chemotherapy, Drug–Drug Interaction, Oncology Pharmacy Programs/Protocols, Oral Therapy
Implementation of a Cardio-Oncology Pharmacist Position in a Community Cancer Center
Marcela W. Heiss, PharmD, BCOP; Robert Mancini, PharmD, BCOP, FHOPA; Chase Ayres, PharmD, BCOP
Read More
Clinical Trials
Pirtobrutinib in Covalent BTKi-Treated Patients With CLL/SLL: Translating Clinical Trial Insights Into Real-World Practice
Read More
CDK4/6 Inhibitors for Treatment of High-Risk, HR-Positive/HER2-Negative Early Breast Cancer: Addressing Tolerability to Maximize Treatment Persistence
Read More
Original Research, Adverse Events
Analysis of Ifosfamide-Associated Encephalopathy Between 2 Formulations in Adults With Hematologic Cancer
Karin M. Abernathy, PharmD, BCOP; Colleen McCabe, PharmD, BCOP; Matt Perciavalle, PharmD, BCPS, BCOP; Manuel G. Cortez, PharmD, BCOP; Ryan M. Miller, PharmD, BCOP; Bradley Yelvington, PharmD, BCOP; Vicki L. Keedy, MD, MSCI
Read More
Original Research, Biosimilars
A Survey of Biosimilar Adoption Across Oncology Pharmacy Practices
Marina Reed, PharmD, BCOP; Eugene R. Przespolewski, PharmD, BCOP, DPLA; Mark Walsh, PharmD, BCOP, DPLA; Catherine Forbes, PharmD; Michelle Amsler, PharmD, BCOP; Kristopher Attwood, PhD; Grazyna Riebandt, PharmD, BCOP, DPLA
Read More
Original Research, Adverse Events, Immunotherapy
Evaluation of Serious Immune-Related Adverse Event Incidence in 200-mg Versus 400-mg Pembrolizumab Regimens
Arlet Bacallao Molina, PharmD; Natoya Muirhead, PharmD, BCOP; Erika Rugay, PharmD, BCOP; Karin Thatcher, PharmD, BCPS; Jovino Hernandez, PharmD, BCPS
Read More
Review Article
Azacitidine in Peripheral T-Cell Lymphoma: Prime Time for Epigenetic Modification?
Taylor S. White, PharmD, BCOP; Joseph B. Elmes, PharmD, BCOP; Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP
Read More
The Impact of Underutilizing Adjuvant CDK4/6 Inhibitors in Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer
Read More
Online First
Original Research, Chemotherapy, Adverse Events
Evaluation of Bleeding Events in Patients Who Received Ibrutinib With or Without Antithrombotic Therapy
Frank A. Lattuca, PharmD, BCOP; Jeremiah E. Moore, PharmD, BCOP; Carissa Treptow, PharmD, BCOP; Kendra Delibert, PharmD, BCOP; Andrea Baran, MS; Clive S. Zent, MD
Read More
Page 8 of 199
Results 71 - 80 of 1986